Report Title:
Total Artificial Heart - Medical Devices Pipeline Assessment, 2017 Published On: May 2017
Category: Life Sciences
Pages: 54
Report Overview: Total Artificial Heart Medical Devices Pipeline Assessment, 2017 Summary GlobalDatas Medical Devices sector report, “Total Artificial Heart Medical Devices Pipeline Assessment, 2017" provides an overview of Total Artificial Heart currently in pipeline stage. The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Total Artificial Heart pipeline products. This report is prepared using data sourced from inhouse databases, secondary and primary research by GlobalDatas team of industry experts. *Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type. Scope Extensive coverage of the Total Artificial Heart under development The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities The report reviews the major players involved in the development of Total Artificial Heart and list all their pipeline projects The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage The report provides key clinical trial data of ongoing trials specific to pipeline products Recent developments in the segment / industry Reasons to buy The report enables you to Formulate significant competitor information, analysis, and insights to improve R&D strategies Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage Identify and understand important and diverse types of Total Artificial Heart under development Develop marketentry and market expansion strategies Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline Indepth analysis of the product’s current stage of development, territory and estimated launch date
24marketreports | International +1 646 781 7170 | www.24marketreports.com
Table of Contents: 1 Table of Contents 1 Table of Contents 2 1.1 List of Tables 4 1.2 List of Figures 5 2 Introduction 6 2.1 Total Artificial Heart Overview 6 3 Products under Development 7 3.1 Total Artificial Heart Pipeline Products by Stage of Development 7 3.2 Total Artificial Heart Pipeline Products by Territory 8 3.3 Total Artificial Heart Pipeline Products by Regulatory Path 9 3.4 Total Artificial Heart Pipeline Products by Estimated Approval Date 10 3.5 Total Artificial Heart Ongoing Clinical Trials 11 4 Total Artificial Heart Pipeline Products under Development by Companies 12 4.1 Total Artificial Heart Companies Pipeline Products by Stage of Development 12 4.2 Total Artificial Heart Pipeline Products by Stage of Development 13 5 Total Artificial Heart Companies and Product Overview 14 5.1 Abiomed Inc Company Overview 14 5.1.1 Abiomed Inc Pipeline Products & Ongoing Clinical Trials Overview 14 5.2 BiVacor Pty Ltd Company Overview 16 5.2.1 BiVacor Pty Ltd Pipeline Products & Ongoing Clinical Trials Overview 16 5.3 Carmat SAS Company Overview 17 5.3.1 Carmat SAS Pipeline Products & Ongoing Clinical Trials Overview 17 5.4 Cleveland Heart Inc Company Overview 20 5.4.1 Cleveland Heart Inc Pipeline Products & Ongoing Clinical Trials Overview 20 5.5 FosterMiller, Inc. Inactive Company Overview 21 5.5.1 FosterMiller, Inc. Inactive Pipeline Products & Ongoing Clinical Trials Overview 21 5.6 Indian Institute of Technology Delhi Company Overview 22 5.6.1 Indian Institute of Technology Delhi Pipeline Products & Ongoing Clinical Trials Overview 22 5.7 ReliantHeart, Inc. Company Overview 23 5.7.1 ReliantHeart, Inc. Pipeline Products & Ongoing Clinical Trials Overview 23 5.8 SynCardia Systems, Inc. Company Overview 24 5.8.1 SynCardia Systems, Inc. Pipeline Products & Ongoing Clinical Trials Overview 24 5.9 The University of Tokyo Company Overview 30 5.9.1 The University of Tokyo Pipeline Products & Ongoing Clinical Trials Overview 30 6 Total Artificial Heart Recent Developments 31 6.1 May 04, 2017: Abiomed Announces Q4 FY 2017 Revenue of $124.7 Million, Up 33% Over Prior Year and Total Year Revenue of $445.3 Million, Up 35% Over Prior Year 31 6.2 May 02, 2017: CARMAT announces the resumption of the PIVOTAL study in France 32 6.3 Apr 19, 2017: Turkish Man Becomes World’s Longest Supported Total Artificial Heart Patient 32 6.4 Mar 14, 2017: SynCardia Names New VP of Manufacturing and Facilities 33 6.5 Feb 06, 2017: CARMAT provides an update regarding the suspended PIVOTAL study on its
24marketreports | International +1 646 781 7170 | www.24marketreports.com
bioprosthetic artificial heart 34 6.6 Jan 26, 2017: Abiomed Announces Q3 FY 2017 Revenue of $114.7 Million, Up 34% Over Prior Year 34 6.7 Jan 25, 2017: Two Cardiology Experts Join CARMAT’s Board of Directors as Independent Members 35 6.8 Jan 09, 2017: Abiomed Announces Preliminary Q3 FY 2017 Revenue of $114.7 Million, Up 34% Over Prior Year 36 6.9 Jan 04, 2017: Clínica Universidad de Navarra Implants Spain’s First SynCardia Total Artificial Heart 37 6.10 Nov 30, 2016: Update on the PIVOTAL study on the CARMAT bioprosthetic artificial heart 38 6.11 Nov 09, 2016: Arrhythmia Research Technology Reports 2016 Third Quarter Results 38 6.12 Oct 27, 2016: Abiomed Announces Q2 FY 2017 Revenue of $103 Million, Up 35% Over Prior Year 40 6.13 Oct 27, 2016: Amedisys Previews Third Quarter 2016 Results 41 6.14 Oct 04, 2016: EKN Duisburg Becomes First DeviceOnly Center to Reach 50 SynCardia Artificial Heart Implants 41 6.15 Sep 08, 2016: CARMAT: 2016 halfyear results in line with the progress achieved by the Company 42 6.16 Sep 01, 2016: CARMAT announces the departure of Marcello Conviti, CEO 43 6.17 Sep 01, 2016: Stephane Piat, Previously Division Vice President of Abbott in California, Has Been Appointed CEO of CARMAT 43 6.18 Aug 29, 2016: CARMAT Announces the Start of the PIVOTAL Study 44 6.19 Aug 16, 2016: SynCardia Artificial Heart to Emerge from Chapter 11 Reorganization With New Owner on September 16, 2016 45 6.20 Aug 11, 2016: Arrhythmia Research Technology Reports 2016 Second Quarter Results 46 6.21 Jul 28, 2016: Abiomed Announces Q1 FY 2017 Revenue of $103.0 Million, Up 40% Over Prior Year 48 6.22 Jul 13, 2016: CARMAT has obtained the necessary approvals to begin the PIVOTAL study in France 49 6.23 Jun 23, 2016: CARMAT has begun, with DEKRA, the CE certification process for its bioprosthetic artificial heart 49 7 Appendix 51 7.1 Methodology 51 7.2 About GlobalData 54 7.3 Contact Us 54 7.4 Disclaimer 54
Get More Information about the Report: Report URL: https://www.24marketreports.com/life-sciences/total-artificial-heart---medical-devices-pipeline-
24marketreports | International +1 646 781 7170 | www.24marketreports.com
assessment-2017 To get Report Sample: https://www.24marketreports.com/request-sample/total-artificial-heart---medical-devices-pipeli ne-assessment-2017
24marketreports | International +1 646 781 7170 | www.24marketreports.com